Selected article for: "case control and Time period"
Author: Gupta, D.; Kulkarni, R.; Pujari, S.; Mulay, A.
Title: COVID-19 ASSOCIATED MUCORMYCOSIS: A CASE-CONTROL STUDY
  • Cord-id: usdfkhvp
  • Document date: 2021_8_20
    • ID: usdfkhvp
    Snippet: Background: India has seen a surge in COVID-19 associated mucormycosis (CAM) cases during the second wave of the pandemic. We conducted a study to determine independent risk factors for CAM. Methods: We performed a retrospective case control study in a tertiary care private hospital in Pune, India. Fifty-two cases of CAM were compared with 166 concurrent controls randomly selected from the COVID-19 admissions during the same time period. Association of demographic factors, comorbidities, cumulat
    Document: Background: India has seen a surge in COVID-19 associated mucormycosis (CAM) cases during the second wave of the pandemic. We conducted a study to determine independent risk factors for CAM. Methods: We performed a retrospective case control study in a tertiary care private hospital in Pune, India. Fifty-two cases of CAM were compared with 166 concurrent controls randomly selected from the COVID-19 admissions during the same time period. Association of demographic factors, comorbidities, cumulative steroid dose used (calculated as dexamethasone equivalent), maximum respiratory support required, use of injectable/oral anticoagulation, and use of aspirin with CAM was assessed by univariate and multivariate logistic regression. Results: A total of 218 subjects (52 cases; 166 controls) were studied. Any diabetes (pre-existing diabetes and new onset diabetes during COVID-19) was noted in a significantly higher proportion of cases (73.1%, 45.8% P<0.001) and cumulative dexamethasone dose used in cases was significantly greater (97.72 mg vs 60 mg; P=0.016). In a multivariate regression analysis cumulate dexamethasone dose >120 mg (OR 9.03, confidence interval 1.75-46.59, P=0.009) and any diabetes (OR 4.78, confidence interval 1.46-15.65, P=0.01) were found to be risk factors for CAM. While use of anticoagulation (OR 0.01, confidence interval 0.00-0.09, P<0.001) and use of aspirin (OR 0.02, confidence interval 0.01-0.07, P<0.001) were found to be protective against CAM. Conclusion: Diabetes mellitus and cumulative dose of dexamethasone greater than 120 mg (or equivalent dose of other corticosteroid) were associated with an increased risk of CAM while use of aspirin and anticoagulation were associated with a lower risk.

    Search related documents:
    Co phrase search for related documents
    • accurate record and logistic regression model: 1
    • accurate record and logistic regression multivariate: 1
    • additional study and admission prior: 1
    • additional study and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
    • additional study and logistic regression analysis: 1, 2, 3
    • additional study and logistic regression multivariate: 1
    • additional study and lymphocyte ratio: 1, 2
    • additional study test and logistic regression: 1
    • additional study test and logistic regression analysis: 1
    • admission prior and lmwh molecular weight heparin: 1, 2
    • admission prior and logistic regression: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • admission prior and logistic regression analysis: 1, 2, 3, 4, 5, 6, 7, 8
    • admission prior and logistic regression model: 1, 2, 3, 4, 5
    • admission prior and logistic regression multivariate: 1, 2, 3, 4, 5, 6, 7, 8
    • admission prior and long duration: 1
    • admission prior and low lmwh molecular weight heparin: 1, 2
    • admission prior and lymphocyte ratio: 1, 2
    • lmwh molecular weight heparin and low lmwh molecular weight heparin: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • lmwh molecular weight heparin and lymphocyte ratio: 1